CareDx Q2 Earnings Call Highlights
CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.
How this was made
The 30-second read
Why it matters
The finalized Medicare policy (effective end of August) removes a previously embedded $7.5M potential impact from the outlook and may improve visibility into surveillance molecular testing coverage. Management also provided detailed full-year and Q3/Q4 test-volume and revenue guidance, plus specialty oncology volume growth and ASP trajectory assumptions.
Market read
Traders can update near-term expectations using explicit guidance ranges for tests, revenue, and gross margin, while also adjusting reimbursement risk after the Medicare LCD finalization.
What to watch
The guidance depends on test volume assumptions (transplant vs specialty oncology mix) and on NavDx integration and billing transition, which could create near-term friction even with favorable coverage.
Background
CareDx’s Q2 call focused on transplant surveillance and for-cause testing adoption, Medicare LCD coverage finalization, and pipeline integration (NavDx, AlloHeme, HistoMap).
Ticker impact
CareDx guided full-year testing volume (258,000 to 266,000 tests) and revenue mix, plus Q3/Q4 test assumptions and margin outlook.
Likely modest positive bias as traders price in clearer coverage pathway and specialty oncology volume growth, though magnitude depends on how guidance compares to Street expectations.
The article provides specific forward-looking numbers (volume, revenue, gross margin) and a finalized Medicare policy removing a $7.5M embedded impact, both of which can move near-term estimates and sentiment.
Market effects
Transplant diagnostics and molecular testing peers may see read-across from finalized Medicare coverage language and adoption commentary.
No clear regional-specific impact beyond US reimbursement policy relevance.
Limited, as the key catalyst is US Medicare LCD coverage and US transplant testing adoption.
Counterpoint
Specialty oncology ASP assumptions are still far below potential end-state ($1,000 to $1,100), so upside may be contingent on execution and payer acceptance.
Key entities
- companyCareDx
Precision diagnostics company providing transplant monitoring tests (AlloMap, AlloSure) and specialty oncology MRD platform (NavDx).
- regulatoryMedicare Local Coverage Determination (LCD)
Finalized policy affirming coverage for surveillance molecular testing in kidney, heart, and lung transplantation, effective end of August.
- productAlloHeme
Recurrence-monitoring test for cell-therapy patients in AML/MDS, targeting a 2027 commercial launch.
- productHistoMap
Molecular biopsy assessment for indeterminate/inconsistent biopsy findings, with kidney launch planned in a clinical study this year and broader availability in 2027.
- productNavDx
Solid-tumor MRD platform, with integration efforts focused on commercial adoption and revenue-cycle management after the July 1 acquisition close.
